4 Healthcare Stock Stories For Thursday Investing Wellness

Johnson & Johnson (NYSE:JNJ): Closing price $87.45

J&J’s Janssen Biotech announced Thursday that the FDA has cleared Simponi (golimumab) for the treatment of moderately to severely active ulcerative colitis in adult patients who have shown corticosteroid dependence, or who have had an inadequate response to or could not tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine. The drug is the first and exclusive subcutaneously administered anti-tumor necrosis factor TNF-alpha therapy okayed to induce and maintain clinical response and improve endoscopic appearance of the mucosa during induction. Beyond that, Simponi is indicated to induce clinical remission and achieve and sustain clinical remission in induction responders. Up to 700,000 persons in the United States are affected by UC1, which is a chronic inflammatory bowel disease marked by inflammation and ulceration of the innermost lining of the colon.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

JNJ

TESARO (NASDAQ:TSRO): Closing price $35.88

The oncology-focused biopharmaceutical firm on Thursday announced that final results from a Phase 1 trial of niraparib, which is an inhibitor of poly ADP-ribose polymerase, will be presented at the American Society of Clinical Oncology annual meeting in Chicago. Included in these results are anti-tumor activity and safety data for 100 patients suffering fr0m solid tumors, including 49 patients with high grade serous ovarian cancer and twelve patients with breast cancer. Full, updated results relating to the abstract will be supplied during the investigators’ poster presentation on June 4, 2013.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

TSRO

NeoStem (NYSE:NBS): Closing price $0.59

On Thursday, NeoStem reported the geographic expansion of intellectual property protection of its lead product candidate, AMR-001, with the notice of patent grant in Malaysia (MY-147516-A) and notice of recommendation for patent allowance in the Philippines (1-2008-501074). These patents are in the family of United States patent number 7,794,705 titled “Compositions and Methods of Vascular Injury Repair,” and cover a chemotactic stem cell product enriched for CD34+ cells that treats injury caused by acute myocardial infarction.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

NBS

SciClone Pharmaceuticals (NASDAQ:SCLN): Closing price $4.97

SciClone has announced that it has reached into an agreement with Zensun (Shanghai) Science & Technology Co., Ltd. granting it a license and the exclusive rights in China, Hong Kong, and Macau through which to promote, market, distribute, and sell Neucardin”, a novel, first-in-class therapeutic drug for the treatment of patients suffering from intermediate to advanced chronic heart failure.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

SCLN

Don’t Miss: Can Obamacare Evade the IRS Shadow?

More Articles About:    

More from The Cheat Sheet